Vaginal Disease Clinical Trial
Official title:
Open, Comparative Study To Evaluate The Performance And Safety Of The Medical Device AINARA® Vaginal Gel Versus A Hyaluronic Acid-Based Gel In Late Menopausal Transition Women Affected By Vaginal Dryness
Verified date | January 2020 |
Source | Italfarmaco |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study evaluates treatment with the medical device Ainara® compared to a HA-based gel (Hyalogin) on the improvement of vaginal dryness
Status | Completed |
Enrollment | 50 |
Est. completion date | November 22, 2019 |
Est. primary completion date | November 22, 2019 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 45 Years to 55 Years |
Eligibility |
Inclusion Criteria: - Non-pregnant and in menopausal transition period (late peri-menopause) women following the STRAW criteria and with a break in menstrual periods of at least 60 days, aged = 45 to = 55 years. - Diagnosis of vaginal dryness by subjective dryness, any objective sign of VVA, pH>5 as reported in the AGATA study and VHI < 15. - Body mass index of = 18.5 to = 36 kg/m2. - Females of child bearing potential who agree to use only lubricated condoms or spiral as contraceptives methods, during the full duration of the study. - Able to communicate adequately with the Investigator and to comply with the requirements for the entire study. - Capable of and freely willing to provide written informed consent prior to participating in the study. Exclusion Criteria: - Women in post-menopausal (total cessation of menses for = 1 year from the date of the screening visit). - Malignancy (also leukemic infiltrates) within 5 years prior to day 0 (except for treated basal cell/squamous cell carcinoma of the skin). - Genital bleeding. - Estrogen vaginal treatment during the study period (permitted only if terminated at least 6 months before study). - Systemic estrogen therapy (permitted only if terminated at least 6 months before study). - Subjects with illness, or other medical condition that, in the opinion of the investigator, would compromise participation or be likely to lead to hospitalization during the course of the study. - Clinical evidence of acute infection currently requiring treatment (syphilis, herpes simplex, human papilloma virus, gonorrhoea, chlamydia, lymphogranuloma venereum, etc.); clinical evidence or history of chronic infectious disease (i.e. tuberculosis). - Psychosis, schizophrenia, mania, depressive disorders, history of suicide attempt or suicidal ideation, or any other psychiatric illness (except for intermittent anxiety). - Known allergy to tested IMDs or its excipients. - Drug or alcohol abuse within 12 months of Day 0. - Participation in an interventional clinical study or administration of any investigational agents in the previous 30 days. - Presence of any clinically significant medical condition judged by the investigator to preclude the patient's inclusion in the study |
Country | Name | City | State |
---|---|---|---|
Romania | Fizio Center | Timisoara | Timis |
Lead Sponsor | Collaborator |
---|---|
Italfarmaco | Opera CRO, a TIGERMED Group Company |
Romania,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The Vaginal Health Index (VHI) | The changing from baseline to day 30 (final visit) for VHI mean value in each group separately and the changing in the Ainara® group in comparison with that occurred in HyaloGyn® group; The minim score is 5 and the maxim is is 25 | 30 days | |
Primary | Visual Analogue Scale (VAS) | The changing from baseline to day 3, 7, 21, 30 (final visit) for VAS mean value in each group separately and in the Ainara® group in comparison with that occurred in HyaloGyn® group. The minim score is 0 and the maxim score is 5, where 0 represents no symptoms and 3 represents severe symptoms | 30 days | |
Secondary | subjective symptoms | Subjective symptoms dryness, itching, burning, dyspareunia, and dysuria reported on patient diary and scored as reported in the AGATA study as follows: 0 = absence, 1 = slight, 2 = moderate, and 3 = severe intensity. The change in these variables will be evaluated from baseline to day 3, 7, 21, 30 (final visit). |
30 days | |
Secondary | objective signs in the vaginal mucosa | Objective signs in the vaginal mucosa: dryness, thinning rugae, pallor, fragility, and petechiae scored as reported in the AGATA study as follows: 0 = absence, 1 = slight, 2 = moderate, and 3 = severe alteration. For these variables will be evaluated the changing from baseline to day 3, 7, 21, 30 (final visit) with comparison intra and inter groups. |
30 days | |
Secondary | Vaginal pH | It will be measured by the Investigators with a test strip delivered by Sponsor. The baseline values can be from 5.0 (this was the minimum value need for vaginal atrophy diagnosis in AGATA study) to 9.0. The Investigator will insert the pH strip into the upper wall of the vagina and will consider the reading made while the strip is still damp. For this outcome will be analysed the changing of mean values from baseline to 30 day (final visit) with comparison intra and inter groups. | 30 days | |
Secondary | Vaginal Trophism Maturation Value (MV) | Vaginal Trophism Maturation Value (MV): this outcome will be obtained from the cellular count of the vaginal smears at baseline and at the 30 days visit. The samples will be fixed, stored, and sent in the local laboratory in Timisoara, Romania (address details in TMF) for staining (Papanicolaou technique) and subsequent analysis. Samples will be evaluated by one independent cytopathologist blinded to the treatment. The MV will be calculated according to the following: MV = [1x (% superficial cells)] + [0.6x (% intermediate cells)] + [0.2x (% parabasal cells)]. The comparison intra and inter groups will be between baseline values and 30 days values. | 30 days | |
Secondary | Female Sexual Function Index (FSFI) | Female Sexual Function Index (FSFI) Romanian version, evaluated by Investigator and analysed considering the changing from baseline to 30 days (final visit) with comparison intra and inter groups. | 30 days | |
Secondary | Sexual Function (SF 12) | SF 12 (Romanian version) evaluated by Investigator and analysed considering the changing from baseline to 30 day (final visit) with comparison intra and inter groups. | 30 days | |
Secondary | Global Symptom Score (GSS) | Global Symptom Score (GSS) a composite score of symptoms, will be obtained to assess the effect of treatment on all individual symptoms taken as a whole. It will be calculated by the addition of the intensity scores of all individual symptoms (range, 1-15: 1 = only mild vaginal dryness, 15 = all five symptoms severe in intensity). This outcome will be compared intra and inter groups, assessing the changing from baseline visit to 30 days visit (final visit). | 30 days | |
Secondary | Patient Global Assessment of Safety (PGAS) | Patient Global Assessment of Safety (PGAS): it will be reported by the subject at all visits and all phone contacts in the patient diary using the 4-point scale: 1= very good safety, 2 = good safety, 3 = moderate safety and 4 = poor safety. |
30 days | |
Secondary | Investigator Global Assessment of Safety (IGAS) | Investigator Global Assessment of Safety (IGAS): it will be reported by the Investigator using the 4-point scale: 1= very good safety, 2 = good safety, 3 = moderate safety and 4 = poor safety. IGAS will be evaluated at the last visit, only. |
30 days | |
Secondary | Adverse Event, Adverse Device Event, Serious Adverse Event, Suspected Adverse Device Event | AE, ADE, SAE, SADE: they will be reported by the Investigators according to the current legislation. All adverse events will be collected by Investigators at all visits and phone contacts and evaluated considering the change from baseline. | 30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04245358 -
Open Non-Comparative Clinical Trial Study To Evaluate The Performance And Safety Of Ainara®
|
N/A | |
Active, not recruiting |
NCT04664985 -
Evaluation of Mucogyne® Ovule in Vulvovaginal Dryness Management in Women Treated by Brachytherapy and/or Radiotherapy for Endometrial or Cervical Cancer.
|
N/A | |
Completed |
NCT04327947 -
Evaluation of Gynecological Acceptability of 3 Health Care Products
|
N/A | |
Recruiting |
NCT05587283 -
Safety, Tolerability, and Acceptability Study of Intravaginal Administration of LABTHERA-001 Capsules in Healthy Women
|
Phase 1 | |
Completed |
NCT05888116 -
Efficacy and Safety of a Hyaluronic Acid-Based Vaginal Moisturizer Medical Device to Ease Symptoms of Vaginal Dryness
|
N/A | |
Not yet recruiting |
NCT00890487 -
Hyaluronic Acid and Vaginal Distress
|
N/A | |
Completed |
NCT04362371 -
Post Marketing Follow Up Study To Evaluate Performance Safety Quality of Menopausal Transition Women Treated With Ainara
|
N/A | |
Completed |
NCT05817292 -
Study of the Vaginal Microbiota in Women Under Fertile Age
|
||
Completed |
NCT05872178 -
Omegia Softgel Clinical Research Program
|
N/A |